Influence of age on the clinical outcome of breast cancer for men and the development of second primary cancers Journal Article


Authors: Cronin, P. A.; Romanoff, A.; Zabor, E. C.; Stempel, M.; Eaton, A.; Smyth, L. M.; Ho, A. Y.; Morrow, M.; El-Tamer, M.; Gemignani, M. L.
Article Title: Influence of age on the clinical outcome of breast cancer for men and the development of second primary cancers
Abstract: Background: Low incidence of breast cancer in men (BCM) (< 1% of all breast cancers) has led to a paucity of outcome data. This study evaluated the impact of age on BCM outcomes. Methods: For this study, BCM patients treated between 2000 and 2011 were stratified by age (≤ 65 or > 65 years). Kaplan–Meier methods were used to compare overall survival (OS) and breast cancer-specific survival (BCSS). Competing-risk methods analyzed time to second primary cancers (SPCs), with any-cause death treated as a competing risk. Results: The study identified 152 BCM patients with a median age of 64 years (range 19–96 years). The median body mass index (BMI) was 28 kg/m2. Men age 65 years or younger (n = 78, 51%) were more overweight/obese than men older than 65 years (n = 74, 49%) (89% vs 74%, respectively; P = 0.008). Both groups had similar nodal metastases rates (P = 0.4), estrogen receptor positivity (P = 1), and human epidermal growth factor receptor 2 (HER2)neu overexpression (P = 0.6). Men 65 years of age or younger were more likely to receive chemotherapy (P = 0.002). The median follow-up period was 5.8 years (range 0.1–14.4 years). The 5-year OS was 86% (95% confidence interval [CI] 80–93%), whereas the 5-year BCSS was 95% (95% CI 91–99%). The BCM patients 65 years of age and younger had better OS (P = 0.003) but not BCSS (P = 0.8). The 5-year cumulative incidence of SPC was 8.4% (95% CI 3.4–13.4%). The prior SPC rate was higher for men older than 65 years (n = 20, 31%) than for those age 65 years or younger (n = 7, 11%) (P = 0.008). This did not account for differences in life years at risk. No difference was observed in SPC cumulative incidence stratified by age (P = 0.3). Conclusions: Men 65 years of age or younger received more chemotherapy and had improved OS, but not BCSS, compared with men older than 65 years. For all BCM, SPC is a risk, and appropriate screening may be warranted. © 2018, Society of Surgical Oncology.
Journal Title: Annals of Surgical Oncology
Volume: 25
Issue: 13
ISSN: 1068-9265
Publisher: Springer  
Date Published: 2018-12-01
Start Page: 3858
End Page: 3866
Language: English
DOI: 10.1245/s10434-018-6767-0
PUBMED: 30298320
PROVIDER: scopus
PMCID: PMC6234073
DOI/URL:
Notes: Article -- Export Date: 3 December 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Alice Yoosun Ho
    109 Ho
  2. Monica Morrow
    434 Morrow
  3. Mary L Gemignani
    139 Gemignani
  4. Emily Craig Zabor
    119 Zabor
  5. Anne Austin Eaton
    112 Eaton
  6. Michelle Moccio Stempel
    123 Stempel
  7. Lillian   Smyth
    20 Smyth
  8. Patricia Ann Cronin
    5 Cronin